In a nutshell This study aimed to investigate the combination of alpelisib (Piqray) and fulvestrant (Faslodex) in patients with PIK3CA-mutated, hormone receptor-positive (HR+), human epidermal growth factor 2 (HER2) negative, advanced breast cancer (BC). This study concluded that this combination provided positive outcomes for...
Read More
In a nutshell This study compared the safety of two hormonal medications used to treat breast cancer, tamoxifen (Nolvadex) and letrozole (Femara). This study found that tamoxifen was associated with an increased risk of blood clots, while letrozole was associated with an increased risk of angina and heart attacks. Some background Hormone-positive...
Read More
In a nutshell The study evaluated outcomes of lapatinib (Tykerb), trastuzumab (Herceptin), and aromatase inhibitor (AI) in postmenopausal women with human epidermal growth factor receptor 2-positive (HER2+) and hormone receptor-positive (HR+) metastatic breast cancer (MBC). The authors found that the combination was safe and effective in such...
Read More
In a nutshell This trial is aiming to investigate the effectiveness of stereotactic body radiotherapy (SBRT) boost for the treatment in patients with high-risk prostate cancer (PCa). The main outcome that will be measured will be the quality of life (QoL) of patients. This study is being carried out in Ontario, Canada. The details PCa is the...
Read More
In a nutshell The study looked at the sequence of dose-escalated radiotherapy (RT) and androgen-deprivation therapy (ADT) in the treatment of local prostate cancer (LPCa). The study found that treatment with ADT before RT had the same outcome as treatment with ADT and RT at the same time. Some background LPCa is a form of cancer that is...
Read More
In a nutshell This study examined the effectiveness of three commonly used therapies to prevent bone loss in patients with hormone-positive breast cancer (BC). The results showed that the therapies prevented bone loss and fractures but to different degrees. Some background Many patients with BC are classified as hormone-positive. This means...
Read MoreIn a nutshell The study looked at the effects of long term androgen deprivation therapy (LT-ADT), pelvic lymph node radiotherapy (PLNRT) and prostate bed radiotherapy (PBRT) in patients with prostate cancer and high risk of recurrence after prostate surgery. They found an increase in survival without cancer worsening in these patients. Some...
Read MoreIn a nutshell This study evaluated the long-term outcomes of docetaxel (Taxotere) plus hormone therapy for patients with metastatic prostate cancer (cancer that spread outside the prostate). This study found that this treatment combination improved survival for these patients, regardless of tumor burden. Some background One treatment for...
Read MoreIn a nutshell This study examined if anti-androgen therapy for prostate cancer is associated with depression. This study concluded that the risk of depression is increased in these patients. Some background Anti-androgen therapy or androgen deprivation therapy (ADT) is commonly used in the treatment of prostate cancer. Androgens (such as...
Read MoreIn a nutshell This study aimed to investigate the effect of the length of androgen deprivation therapy (ADT) when used with radiotherapy in patients with prostate cancer. This study found that 18 months ADT led to similar overall survival and better quality of life as compared to 36 months in these patients. Some background...
Read MoreIn a nutshell This study aimed to compare two hormone therapies, gonadotropin-releasing hormone (GnRH) agonists and anti-androgen therapy (AA) in men with advanced, non-metastatic prostate cancer. This study found that the two therapies have similar outcomes, but by starting with AA treatment may reduce side effects associated with GnRH...
Read MoreIn a nutshell This study wanted to find out if continuing hormone therapy for 10 years was more effective than doing it for 5 years in patients with early stage breast cancer. The study found that the patients who continued treatment for 10 years survived for longer without the disease coming back compared to those who were only treated for 5...
Read More
